CL2020000356A1 - Composiciones farmacéuticas. - Google Patents

Composiciones farmacéuticas.

Info

Publication number
CL2020000356A1
CL2020000356A1 CL2020000356A CL2020000356A CL2020000356A1 CL 2020000356 A1 CL2020000356 A1 CL 2020000356A1 CL 2020000356 A CL2020000356 A CL 2020000356A CL 2020000356 A CL2020000356 A CL 2020000356A CL 2020000356 A1 CL2020000356 A1 CL 2020000356A1
Authority
CL
Chile
Prior art keywords
pharmaceutical compositions
compound
active ingredient
compositions
dórula
Prior art date
Application number
CL2020000356A
Other languages
English (en)
Inventor
Stephen John Pethen
Gary Cook
Sally Louise Marsh
Michael Bryan Roe
Christopher Martyn Yea
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1713660.7A external-priority patent/GB201713660D0/en
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of CL2020000356A1 publication Critical patent/CL2020000356A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON COMPOSICIONES FARMACÉUTICAS EN SOLUCIÓN ACUOSA QUE COMPRENDEN POR LO MENOS UN AGENTE DE TONICIDAD NO IÓNICO, POR LO MENOS UNA SOLUCIÓN TAMPÓN Y UN INGREDIENTE ACTIVO, CARACTERIZADAS PORQUE DICHO INGREDIENTE ACTIVO ES UN COMPUESTO DE LA FÓRMULA I, DONDE R1-R9 ESTÁN DEFINIDOS EN EL PRESENTE DOCUMENTO; LOS PROCESOS PARA LA PREPARACIÓN DE ESTAS COMPOSICIONES Y SU USO EN MEDICINA, EN ESPECIAL SU USO EN EL TRATAMIENTO DE LAS ENFERMEDADES OCULARES.
CL2020000356A 2017-08-11 2020-02-11 Composiciones farmacéuticas. CL2020000356A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762544346P 2017-08-11 2017-08-11
GBGB1713660.7A GB201713660D0 (en) 2017-08-25 2017-08-25 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CL2020000356A1 true CL2020000356A1 (es) 2020-06-19

Family

ID=70976595

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000356A CL2020000356A1 (es) 2017-08-11 2020-02-11 Composiciones farmacéuticas.

Country Status (8)

Country Link
CL (1) CL2020000356A1 (es)
CO (1) CO2020002287A2 (es)
EC (1) ECSP20017939A (es)
IL (1) IL272428A (es)
MX (1) MX2020001356A (es)
PH (1) PH12020500246A1 (es)
RU (1) RU2020109955A (es)
UA (1) UA125537C2 (es)

Also Published As

Publication number Publication date
MX2020001356A (es) 2020-03-20
CO2020002287A2 (es) 2020-06-09
ECSP20017939A (es) 2020-04-22
UA125537C2 (uk) 2022-04-13
PH12020500246A1 (en) 2021-03-15
RU2020109955A (ru) 2021-09-14
IL272428A (en) 2020-03-31
RU2020109955A3 (es) 2022-01-24

Similar Documents

Publication Publication Date Title
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
CL2017002636A1 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
DOP2017000270A (es) Composiciones farmacéuticas tópicas
CL2020001762A1 (es) Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464)
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
CL2020002252A1 (es) Formulación oftálmica.
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY37741A (es) Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
UY37496A (es) Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo
UY37789A (es) Nuevos derivados de azaquinolina
CL2016002276A1 (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad
UY37705A (es) Nuevos derivados de pirazol bicíclicos
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
UY37577A (es) Dihidroimidazopiridindionas sustituidas
PE20171246A1 (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
AR110250A1 (es) Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
BR112019005578A2 (pt) compostos de indazol para uso em lesões no tendão e/ou ligamento
CL2020000356A1 (es) Composiciones farmacéuticas.